Multibacillary leprosy patients with high and persistent serum antibodies to leprosy IDRI diagnostic-1/LID-1: higher susceptibility to develop type 2 reactions

Autor: Danielle de Freitas Mizoguti, Emerith Mayra Hungria, Aline Araújo Freitas, Regiane Morillas Oliveira, Ludimila Paula Vaz Cardoso, Mauricio Barcelos Costa, Ana Lúcia Maroclo Sousa, Malcolm S Duthie, Mariane Martins Araújo Stefani
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Zdroj: Memorias do Instituto Oswaldo Cruz, Vol 110, Iss 7, Pp 914-920 (2015)
Druh dokumentu: article
ISSN: 1678-8060
0074-0276
DOI: 10.1590/0074-02760150198
Popis: Leprosy inflammatory episodes [type 1 (T1R) and type 2 (T2R) reactions] represent the major cause of irreversible nerve damage. Leprosy serology is known to be influenced by the patient’s bacterial index (BI) with higher positivity in multibacillary patients (MB) and specific multidrug therapy (MDT) reduces antibody production. This study evaluated by ELISA antibody responses to leprosy Infectious Disease Research Institute diagnostic-1 (LID-1) fusion protein and phenolic glycolipid I (PGL-I) in 100 paired serum samples of 50 MB patients collected in the presence/absence of reactions and in nonreactional patients before/after MDT. Patients who presented T2R had a median BI of 3+, while MB patients with T1R and nonreactional patients had median BI of 2.5+ (p > 0.05). Anti-LID-1 and anti-PGL-I antibodies declined in patients diagnosed during T1R (p < 0.05). Anti-LID-1 levels waned in MB with T2R at diagnosis and nonreactional MB patients (p < 0.05). Higher anti-LID-1 levels were seen in patients with T2R at diagnosis (vs. patients with T1R at diagnosis, p = 0.008; vs. nonreactional patients, p = 0.020) and in patients with T2R during MDT (vs. nonreactional MB, p = 0.020). In MB patients, high and persistent anti-LID-1 antibody levels might be a useful tool for clinicians to predict which patients are more susceptible to develop leprosy T2R.
Databáze: Directory of Open Access Journals
Externí odkaz: